Leipzig

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma2 trials
• Acute myeloid leukaemia1 trial
• Asthma1 trial
• COPD1 trial
• Lung cancer1 trial
• Lupus (SLE)1 trial
• Myelodysplastic syndromes1 trial

Phase

• Phase 1/22 trials
• Phase 32 trials
• Phase 11 trial
• Phase 21 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• GlaxoSmithKline7 trials

Running trials

• Active, not recruiting

  Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

  NCT07084896· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT04126200· Phase 1/2· GlaxoSmithKline· Source

Closed trials

• Terminated

  A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

  NCT05424380· Phase 1· GlaxoSmithKline· Source

• Completed

  Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04719832· Phase 3· GlaxoSmithKline· Source

• Completed

  Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

  NCT04133909· Phase 3· GlaxoSmithKline· Source

• Completed

  Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

  NCT03739710· Phase 2· GlaxoSmithKline· Source

• Completed

  Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

  NCT01729455· GlaxoSmithKline· Source